Origin Sciences is a diagnostics company focused on diseases of the gastrointestinal tract using a unique biospecimen, being the rectal mucous. Our current research and validation programme targets accurate and efficient triage of patients with symptoms of colorectal cancer (CRC) and/or high-risk colorectal pathology.
CRC is often curable when detected early. Unfortunately, early detection frequently evades current screening protocols due to their expensive, invasive and/or inconvenient nature. With the incidence rate for CRC rising globally, notably among younger age cohorts, there is an overwhelming unmet need for an accurate, convenient, and affordable diagnostic approach.
Our research shows that rectal mucous is the single best biological sample for diagnosing diseases of the GI tract; better than stool; better than blood. Whilst mainstream research has neglected this avenue of liquid biopsy, we have patented a widely-tested proprietary medical device for sample-retrieval, Oricol™. Moreover, our panel of diagnostic tests is showing breakthrough levels of accuracy for what is a rapid and minimally invasive approach.
Whilst validating our unique CRC diagnostic approach is Origin’s primary focus, we are confident that our platform will also help to solve several other GI-linked diagnostic challenges. Importantly, we believe our technology will reduce the burden of unnecessary, expensive and often invasive patient investigations. We are working to improve the accuracy and speed of diagnosis, reduce healthcare cost and save lives.